The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

A federal district court in Texas on Thursday denied a request for a preliminary injunction from the Outsourcing Facilities ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

College of Charleston's Kindred Hurtado examines one woman's weight-loss journey with the assistance of semaglutides.

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits ...

v. U.S. Food and Drug Administration (Case No. 4:24-CV-0953-P) and urges the court to issue a preliminary injunction blocking the FDA's February 2025 decision to remove Semaglutide injections from ...

Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date. (HealthDay News) — For patients with diabetes, semaglutide use is ...

LIKE MANY OTHER PROVIDERS, NP TO-GO OFFERED THEIR PATIENTS COPYCAT VERSIONS OF THE SEMAGLUTIDE FROM COMPOUNDING PHARMACIES, BUT THAT HAS COME TO A HALT AFTER THE FDA DECLARED THERE WAS NO LONGER A ...

He said, “Hey Joe, I’m getting these weird calls about semaglutide.” According to the specialist’s calculations, people were giving themselves 10 times the correct dose. But that didn’t ...